The, system, which will now be part of EndoChoice's Third Generation Fuse Full Spectrum Endoscopy System, analyses and selectively improves the vascularity, surface texture and colours of abnormal tissues.
It offers detailed information for physicians in identifying abnormalities during gastro-intestinal procedures.
Lumos helps in easy detection for physicians and inspection of affected tissue with the help of toggling between two settings. The first setting can selectively enhance tissue and can remain throughout the procedure.
On the other hand, the second setting will help in in-depth detection of suspected tissues when they are identified.
Lumos has been launched earlier this year In several key international markets and EndoChoice claims that physicians are already reaping its benefits through easy detection of abnormal tissues.
EndoChoice founder and CEO Mark Gilreath said: "We are excited to introduce new innovations that continue to deliver on the Fuse brand promise of seeing more.
"We expect that Lumos with Adaptive Matrix Imaging will become an indispensable tool for the GI endoscopist."
